Thursday, February 26, 2026

Novo Nordisk partners with Vivtex on oral biologics

Novo Nordisk and Vivtex Corporation announced on 25 February 2026 a partnership to develop next-generation oral biologic medicines for obesity, diabetes, and related comorbidities.

Aim: enable oral delivery of peptide and protein therapeutics

The collaboration targets biologic drug candidates that are often restricted to injection because absorption in the gastrointestinal tract can be insufficient for oral use. Novo Nordisk will draw on its capabilities in peptide and protein therapeutics, while Vivtex will license selected oral drug-delivery technologies.

Vivtex contributes a proprietary platform combining gastrointestinal screening assays, formulation technologies, and computational simulation with AI-enabled analytics. The approach is designed to identify formulations with high oral bioavailability and consistent performance in humans.

Financial terms and responsibilities

Under the agreement, Vivtex is eligible for upfront consideration, research funding, and milestone payments totaling up to US$2.1 billion, plus tiered royalties on potential future product sales.

After research and formulation selection, Novo Nordisk will take responsibility for global development, regulatory activities, manufacturing, and commercialization of any resulting products.

Company background

Vivtex is a biotechnology company operating in Cambridge, Massachusetts, and Schlieren, Switzerland. Novo Nordisk is a global healthcare company headquartered in Denmark.

More information: novonordisk.com and vivtex.com.